← All trials
NCT07265674
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2027
- First posted
- Dec 5, 2025
- Last posted
- Dec 5, 2025
- Enrollment
- 480
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- J-Pharma Co., Ltd.Lead sponsor
- Memorial Sloan-Kettering Cancer CenterOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.